Last Updated: August 9, 2026

Patent: 11,084,865

✉ Email this page to a colleague

Summary for Patent: 11,084,865

Title:	VEGF antagonist formulations suitable for intravitreal administration
Abstract:	Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Inventor(s):	Furfine Eric, Dix Daniel, Graham Kenneth, Frye Kelly
Assignee:	REGENERON PHARMACEUTICALS, INC.
Application Number:	US16739559
Patent Claims:	see list of patent claims

Details for Patent 11,084,865

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Start Trial	2040-01-10
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Start Trial	2040-01-10
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355	August 18, 2023	⤷ Start Trial	2040-01-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,084,865

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	200809827	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2007149334	⤷ Start Trial
United States of America	10400025	⤷ Start Trial
United States of America	10464992	⤷ Start Trial
United States of America	11066458	⤷ Start Trial
United States of America	11732024	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.